Vesiculovirus neutralization by natural IgM and complement

Journal of Virology

Volumn 88, Issue 11, 2014, Pages 6148-6157

  Tesfay, Mulu Z ^a   Ammayappan, Arun ^a   Federspiel, Mark J ^a   Barber, Glen N ^b   Stojdl, David ^c   Peng, Kah Whye ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG; VIRUS G PROTEIN; VIRUS GLYCOPROTEIN;

ARTICLE; CONTROLLED STUDY; MARABA VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; VESICULAR STOMATITIS VIRUS; VIRUS GENE; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COMPLEMENT SYSTEM PROTEINS; DNA PRIMERS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN M; NEUTRALIZATION TESTS; ONCOLYTIC VIROTHERAPY; VERO CELLS; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS;

EID: 84899807264     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00074-14     Document Type: Article

References (55)

1. Edwards CM, Zhuang J, Mundy GR. 2008. The pathogenesis of the bone disease of multiple myeloma. Bone 42:1007-1013. http://dx. doi. org/10. 1016/j. bone. 2008. 01. 027.
2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. 2007. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. 7:585-598. http://dx. doi. org/10. 1038/nrc2189.
3. Kyle RA, Rajkumar SV. 2004. Multiple myeloma. N. Engl. J. Med. 351: 1860-1873. http://dx. doi. org/10. 1056/NEJMra041875.
4. Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. 2008. Extravasation and homing mechanisms in multiple myeloma. Clin. Exp. Metastasis 25:325-334. http://dx. doi. org/10. 1007/s10585-007-9108-4.
5. Cook R. 2008. Economic and clinical impact of multiple myeloma to managed care. J. Manag. Care Pharm. 14(Suppl):19-25.
6. Kyle RA, Rajkumar SV. 2009. Treatment of multiple myeloma: a comprehensive review. Clin. Lymphoma Myeloma 9:278-288. http://dx. doi. org/10. 3816/CLM. 2009. n. 056.
7. Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, Carreau N, Hideshima T, Anderson KC, Richardson PG. 2009. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 23:2222-2232. http://dx. doi. org/10. 1038/leu. 2009. 179.
8. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (ed). 2007. SEER cancer statistics review, 1975-2004. National Cancer Institute, Bethesda, MD.
9. Schwartz RN, Vozniak M. 2008. Current and emerging treatments for multiple myeloma. J. Manag. Care Pharm. 14:S12-S18.
10. Lichty BD, Stojdl DF, Taylor RA, Miller L, Frenkel I, Atkins H, Bell JC. 2004. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum. Gene Ther. 15:821-831. http://dx. doi. org/10. 1089/hum. 2004. 15. 821.
11. Liu C, Russell SJ, Peng K-W. 2010. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol. Ther. 18:1155-1164. http://dx. doi. org/10. 1038/mt. 2010. 43.
12. Liu TC, Galanis E, Kim D. 2007. Clinical trial with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4:101-117. http://dx. doi. org/10. 1038/ncponc0736.
13. Russell S. 2002. RNA viruses as virotherapy agents. Cancer Gene Ther. 9:961-966. http://dx. doi. org/10. 1038/sj. cgt. 7700535.
14. Russell SJ, Peng K-W, Bell JC. 2012. Oncolytic virotherapy. Nat. Biotechnol. 30:658-670. http://dx. doi. org/10. 1038/nbt. 2287.
15. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. 2007. Oncolytic viruses in cancer therapy. Cancer Lett. 254:178-216. http://dx. doi. org/10. 1016/j. canlet. 2007. 02. 002.
16. Wagner RR, Rose JK. 1996. Rhabdoviridae: the viruses and their replication, p 1121-1135. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PA.
17. Lichty BD, Power AT, Stojdl DF, Bell JC. 2004. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol. Med. 10:210-216. http://dx. doi. org/10. 1016/j. molmed. 2004. 03. 003.
18. Ahmed M, Cramer SD, Lyles DS. 2004. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 330:34-49. http://dx. doi. org/10. 1016/j. virol. 2004. 08. 039.
19. Bergman I, Griffin JA, Gao Y, Whitaker-Dowling P. 2007. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu. Int. J. Cancer 121:425-430. http://dx. doi. org/10. 1002/ijc. 22680.
20. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, Valdes M, Barber G, Vile RG. 2007. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 67:2840-2848. http://dx. doi. org/10. 1158/0008-5472. CAN-06-3974.
21. Ebert O, Harbaran S, Shinozaki K, Woo SL. 2005. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther. 12:350-358. http://dx. doi. org/10. 1038/sj. cgt. 7700794.
22. Ebert O, Shinozaki K, Huang TG, Savontaus MJ, Garcia-Sastre A, Woo SL. 2003. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. 63: 3605-3611.
23. Huang TG, Ebert O, Shinozaki K, Garcia-Sastre A, Woo SL. 2003. Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol. Ther. 8:434-440. http://dx. doi. org/10. 1016/S1525-0016(03)00204-1.
24. Lun X, Senger DL, Alain T, Oprea A, Parato K, Stojdl D, Lichty B, Power A, Johnston RN, Hamilton M, Parney I, Bell JC, Forsyth PA. 2006. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV (deltaM51)) on multifocal and invasive gliomas. J. Natl. Cancer Inst. 98:1546-1557. http://dx. doi. org/10. 1093/jnci/djj413.
25. Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SL. 2004. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol. Ther. 9:368-376. http://dx. doi. org/10. 1016/j. ymthe. 2003. 12. 004.
26. Sung CK, Choi B, Wanna G, Genden EM, Woo SL, Shin EJ. 2008. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Laryngoscope 118:237-242. http://dx. doi. org/10. 1097/MLG. 0b013e3181581977.
27. Wu Y, Lun X, Zhou H, Wang L, Sun B, Bell JC, Barrett JW, McFadden G, Biegel JA, Senger DL, Forsyth PA. 2008. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin. Cancer Res. 14:1218-1227. http://dx. doi. org/10. 1158/1078-0432. CCR-07-1330.
28. Belkowski LS, Sen GC. 1987. Inhibition of vesicular stomatitis viral mRNA synthesis by interferon. J. Virol. 61:653-660.
29. Carey BL, Ahmed M, Puckett S, Lyles DS. 2008. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J. Virol. 82:12104-12115. http://dx. doi. org/10. 1128/JVI. 01508-08.
30. Moerdyk-Schauwecker M, Shah NR, Murphy AM, Hastie E, Mukherjee P, Grdzelishvili VZ. 2013. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology 436:221-234. http://dx. doi. org/10. 1016/j. virol. 2012. 11. 014.
31. Obuchi M, Fernandez M, Barber GN. 2003. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. Virology 77:8843-8856. http://dx. doi. org/10. 1128/JVI. 77. 16. 8843-8856. 2003.
32. Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, Sterman DH, Harty RN, Okumura A, Barber GN, Vile RG, Federspiel MJ, Russell SJ, Litzky L, Albelda SM. 2010. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-β for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum. Gene Ther. 21:51-64. http://dx. doi. org/10. 1089/hum. 2009. 088.
33. Stojdl DE, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:821-825. http://dx. doi. org/10. 1038/77558.
34. Stojdl DF, Lichty BD, ten Oever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin E, Hiscott J, Bell JC. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263-275. http://dx. doi. org/10. 1016/S1535-6108(03)00241-1.
35. Critchley-Thornea RJ, Simonsa DL, Yana N, Miyahiraa AK, Dirbasc FM, Johnsonc DL, Swetterd SM, Carlsone RW, Fishere GA, Koongf A, Holmesb S, Leea PP. 2009. Impaired interferon signaling is a common immune defect in human cancer. Proc. Natl. Acad. Sci. USA. 106:9010-9015. http://dx. doi. org/10. 1073/pnas. 0901329106.
36. Naik S, Nace R, Federspiel MJ, Barber GN, Peng KW, Russell SJ. 2012. Curative one-shot systemic virotherapy in murine myeloma. Leukemia 26:1870-1878. http://dx. doi. org/10. 1038/leu. 2012. 70.
37. Naik S, Nace R, Federspiel MJ, Barber GN, Russell SJ. 2012. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β. Cancer Gene Ther. 19:443-450. http://dx. doi. org/10. 1038/cgt. 2012. 14.
38. Beebe DP, Cooper NR. 1981. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J. Immunol. 126:1562-1568.
39. Tesfay MZ, Kirk AC, Hadac EM, Griesmann GE, Federspiel MJ, Barber GN, Henry SM, Peng KW, Russell SJ. 2013. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. J. Virol. 87:3752-3759. http://dx. doi. org/10. 1128/JVI. 02832-12.
40. Pauszek SJ, Barrera JC, Goldberg T, Allende R, Rodriguez LL. 2011. Genetic and antigenic relationships of vesicular stomatitis viruses from South America. Arch. Virol. http://dx. doi. org/10. 1007/s00705-011-1081-1.
41. Brun J, McManus D, Lefebvre C, Hu K, Falls T, Atkins H, Bell JC, McCart JA, Mahoney D, Stojdl DF. 2010. Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol. Ther. 18:1440-1449. http://dx. doi. org/10. 1038/mt. 2010. 103.
42. Lawson ND, Stillmans EA, Whit MA, Rose JK. 1995. Recombinant vesicular stomatitis viruses from DNA (rhabdovirus/viral replication/viral assembly). Proc. Natl. Acad. Sci. USA. 92:4477-4481. http://dx. doi. org/10. 1073/pnas. 92. 10. 4477.
43. Hosono M, Muramatsu S. 1972. Use of 2-mercaptoethanol for distinguishing between IgM and IgG antibody-producing cells of mice immunized with bovine globulin. J. Immunol. 109:857-863.
44. Travassos da Rosa APA, Mather TN, Takeda T, Whitehouse CA, Shope RE, Popov VL, Guzman H, Coffey L, Araujo TP, Tesh RB. 2002. Two new rhabdoviruses (Rhabdoviridae) isolated from birds during surveillance for arboviral encephalitis, northeastern United States. Emerg. Infect. Dis. 8:614-618. http://dx. doi. org/10. 3201/eid0806. 010384.
45. Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. 2013. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc. Natl. Acad. Sci. USA. 110:7306-7311. http://dx. doi. org/10. 1073/pnas. 1214441110.
46. Brunner KT, Hurez D, McCluskey RT, Benacerraf B. 1960. Blood clearance of p32-labeled vesicular stomatitis and Newcastle disease viruses by the reticuloendothelial system in mice. J. Immunol. 85:99-105.
47. Ferguson MS, Lemoine NR, Wang Y. 31 January 2012. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv. Virol. doihttp://dx. doi. org/10. 1155/2012/805629.
48. Munguia A, Ota T, Miest T, Russell SJ. 2008. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther. 15:797-806. http://dx. doi. org/10. 1038/gt. 2008. 45.
49. Power AT, Bell JC. 2008. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther. 15: 772-779. http://dx. doi. org/10. 1038/gt. 2008. 40.
50. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. 2009. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol. Ther. 17:1667-1676. http://dx. doi. org/10. 1038/mt. 2009. 194.
51. Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, Stojd DF, Forsyth PAJ, Atkins H, Bell JC. 2007. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. 15:123-130. http://dx. doi. org/10. 1038/sj. mt. 6300039.
52. Croyle MA, Callahan SM, Auricchio A, Schumer G, Linse KD, Wilson JA, Brunner LJ, Kobinger GP. 2004. PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum. J. Virol. 78:912-921. http://dx. doi. org/10. 1128/JVI. 78. 2. 912-921. 2004.
53. Hwang BY, Schaffer DV. 2013. Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors. Gene Ther. 20:807-815. http://dx. doi. org/10. 1038/gt. 2013. 1.
54. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, Harsh GR, IV, Louis DN, Bartus RT, Hochberg FH, Chiocca EA. 1999. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5:881-887. http://dx. doi. org/10. 1038/11320.
55. Trobridge GD, Wu RA, Hansen M, Ironside C, Watts KL, Olsen P, Beard BC, Kiem H-P. 2010. Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. Mol. Ther. 18:725-733. http://dx. doi. org/10. 1038/mt. 2009. 282.